Role of 5-hydroxytryptamine3 (5-HT3) antagonists in the prevention of emesis caused by anticancer therapy

Biochemical Pharmacology

Volumn 52, Issue 5, 1996, Pages 685-692

  Karim, Farzana ^a   Roerig, Sandra C ^a   Saphier, David ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

5 HT3 receptor antagonists; 5 HT3 receptors; chemotherapy; emesis; nausea; signal transduction

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; ONDANSETRON; RECEPTOR SUBTYPE; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; ANTINEOPLASTIC AGENT; SEROTONIN RECEPTOR;

CANCER; CHEMOTHERAPY; HUMAN; NAUSEA; PRIORITY JOURNAL; REVIEW; VOMITING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; NAUSEA; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; SIGNAL TRANSDUCTION; VOMITING;

EID: 0030582222     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00346-2     Document Type: Note

References (64)

1. 1. Schofield PR, Shivers BD and Seeburg PH, The role of receptor subtype diversity in the CNS. Trends Neurosci 13: 8-10, 1990.
2. 2. Humphrey PPA, Hartig P and Hoyer D, A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 14: 233-236, 1993.
3. 3. Naylor RJ and Inall FC, The physiology and pharmacology of postoperative nausea and vomiting. Anaesthesia 49( Suppl): 2-5, 1994.
4. 3 receptors in neuronal cell lines. Trends Pharmacol Sci 10: 172-175, 1989.
5. 3 receptor antagonists as antiemetics. Trends Pharmacol Sci 12: 46-48, 1991.
6. 6. Gaddum JH and Picarelli ZP, Two kinds of tryptamine receptor. Br J Pharmacol 12: 323-328, 1957.
7. 3 receptors are membrane ion channels. Nature 339: 706-709, 1989.
8. 3 receptor, a serotonin-gated ion channel. Science 254: 432-437, 1991.
9. 3 receptor-mediated electrical response in cultured mouse neuroblastoma cells. Neuropharmacology 27: 301-307, 1988.
10. 3 receptor from pooled rat cortical and hippocampal membranes. J Neurochem 54: 924-930, 1990.
11. 3 Receptors (Ed. Hamon M), pp. 89-102. Academic Press, San Diego, 1992.
12. 3 receptors. Trends Neurosci 1: 424-428, 1986.
13. 13. Fozard JR, Neuronal 5-HT receptors in the periphery. Neuropharmacology 23: 1473-1486, 1984.
14. 14. Richardson BP, Engel G, Donatsch P and Stadler PA, Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316: 126-131, 1985.
15. 15. Bucheit KH, Engel G, Muthchler E and Richardson BP, Study on the long term contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea pig ileum: Evidence for two distinct release mechanisms. Naunyn Schmiedebergs Arch Pharmacol 329: 36-41, 1985.
16. 3 recognition sites in human brain tissue. J Neurochem 53: 1787-1793, 1989.
17. 3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol 159: 157-164, 1989.
18. 3 receptor recognition sites in the ferret brain stem. Naunyn Schmiedebergs Arch Pharmacol 342: 17-21, 1990.
19. 3 antagonist. J Pharm Pharmacol 40: 301-302, 1988.
20. 3 binding sites solubilized from membranes of NG108-15 neuroblastoma-glioma cells. J Neurochem 5: 1526-1536, 1990.
21. 3H]ICS 205-930. Naunyn Schmiedebergs Arch Pharmacol 337: 493-499, 1988.
22. 3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding. Mol Pharmacol 33: 303-309, 1988.
23. 3 receptors in clonal cell lines studied by patch-clamp techniques. Br J Pharmacol 97: 27-40, 1989.
24. 3 receptor. J Neurophysiol 65: 630-638, 1991.
25. 25. Yang J, Ion permeation through 5-hydroxytryptamine-gated channels in neuroblastoma N18 cells. J Gen Physiol 96: 1177-1198, 1990.
26. 3 Receptors (Ed. Hamon M), pp. 103-128. Academic Press, San Diego, 1992.
27. 2 receptors by different mechanisms. J Cell Sci 93: 545-555, 1989.
28. 28. Dumuis A, Bouhelal R, Sebben M and Bockaert J, A 5-HT receptor in the central nervous system, positively coupled with adenylate cyclase, is antagonized by ICS 205 930. Eur J Pharmacol 146: 187-188, 1988.
29. 3 receptors. Eur J Pharmacol 172: 195-198, 1989.
30. 3 receptor in a rat glioma x mouse neuroblastoma hybrid cell. J Physiol (Lond) 436: 293-308, 1991.
31. 3 receptor-gated currents in adult rat dorsal root ganglion neurones. Br J Pharmacol 102: 272-276, 1991.
32. 3-like receptors in the rat medial prefrontal cortex: An electrophysiological study. Brain Res 550: 181-191, 1991.
33. 3 receptor agonists on phosphoinositide hydrolysis in the rat fronto-cingulate and entorhinal cortices. J Pharmacol Exp Ther 256: 1025-1032, 1991.
34. 3 Receptors (Ed. Hamon M), pp. 129-156. Academic Press, San Diego, 1992.
35. 35. Sagar SM, The current role of anti-emetic drugs in oncology: A recent revolution in patient symptom control. Cancer Treat Rev 18: 95-135, 1991.
36. 36. Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelsen DP, Braun DW Jr, Bordin LA, Braun TJ and Young CW, Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and emesis. N Engl J Med 305: 905-909, 1981.
37. 37. Cubeddu LX, Hoffman IS, Fuenmayor NT and Finn AL, Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and emesis. N Engl J Med 322: 810-816, 1990.
38. 38. Proctor JD, Chremos AN, Evans EF and Wasserman AJ, An apomorphine-induced vomiting model for antiemetic studies in man. J Clin Pharmacol 18: 95-99, 1978.
39. 39. Harding RK, Hugenholtz H, Keaney M and Kucharczyk J, Discrete lesions of the area postrema abolish radiation-induced emesis in the dog. Neurosci Lett 53: 95-100, 1985.
40. 40. Hawthorn J, Ostler KJ and Andrews PR, The role of the abdominal visceral innervation and 5-HT receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cisplatin in the ferret. Q J Exp Physiol 73: 7-21, 1988.
41. 41. Cubeddu LX, Mechanisms by which cancer chemotherapeutic drugs induce emesis. Semin Oncol 19(Suppl 15): 2-13, 1992.
42. 3 receptor antagonists. Oncology 49: 263-268, 1992.
43. 43. Gunning SJ, Hagan RM and Tyers MB, Cisplatin induces biochemical and histological changes in the small intestine of the ferret. Br J Pharmacol 90(Suppl): 135P, 1987.
44. 44. Alfieri AB and Cubeddu LX, Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients. Br J Cancer 71: 629-632, 1995.
45. 45. Wilder-Smith OHG, Borgeat A, Chappuis P, Fathi M and Forni M, Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 72: 2239-2241, 1993.
46. 3 receptor in the anaesthetized ferret. J Physiol (Lond) 422: 92P, 1990.
47. 3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 97: 247-255, 1989.
48. 3H]BRL 43694 binds to presynaptic sites in the nucleus tractus solitarius of the rat. Br J Pharmacol 97(Suppl): 414P, 1989.
49. 3 receptor antagonist granisetron (BRL 43694). Brain Res 565: 231-236, 1991.
50. 4 receptor in zacopride and copper sulfate induced vomiting in the ferret. Eur J Pharmacol 204: 273-280, 1991.
51. 3 receptors prevents cisplatin-induced but not motion-or xylazine-induced emesis in the cat. Pharmacol Biochem Behav 32: 207-210, 1989.
52. 52. Andrews PLR and Bhandari P, The 5-hydroxytryptamine receptor antagonists as antiemetics: Preclinical evaluation and mechanism of action. Eur J Cancer 29A (Suppl 1): S11-S16, 1993.
53. 53. Gandara DR, Harvey WH, Monaghan GG, Perez EA and Hesketh PJ, Delayed emesis following high-dose cisplatin: A double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer 29A(Suppl 1): S35-S38, 1993.
54. 3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology 33: 1607-1608, 1994.
55. 55. Kris MG, Gralla RJ, Clark RA and Tyson LB, Dose-ranging evaluation of the serotonin antagonist GR-C 507/75 (GR 38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. J Clin Oncol 6: 659-662, 1988.
56. 56. Grunberg SM, Stevenson LL, Russell CA and McDermed JE, Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 7: 1137-1141, 1989.
57. 57. Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL and Powell JR, Age and gender effects on ondansetron pharmacokinetics: Evaluation of healthy aged volunteers. Clin Pharmacol Ther 51: 51-55, 1992.
58. 3 receptors. Br J Pharmacol 94: 397-412, 1988.
59. 59. Tyers MB, Pharmacology and preclinical antiemetic properties of ondansetron. Semin Oncol 19(Suppl 10): 1-8, 1992.
60. 3 receptor activation in the rat increases adrenocortical secretion at the level of the central nervous system. Neurosci Res Commun 14: 167-173, 1994.
61. 3 antagonists. Psychoneuroendocrinology 20: 239-257, 1995.
62. 86Rb efflux from human neuroblastoma cells, TE671, by ondansetron. J Pharm Pharmacol 47: 618-622, 1995.
63. 3 antagonist in healthy human subjects. Eur J Clin Pharmacol 46: 159-162, 1994.
64. 3 receptor antagonist and antiemetic properties. Eur J Pharmacol 232: 139-145, 1993.